QuantumCyte, Inc., founded in 2013, is a transformative player in the Biotechnology and Life Sciences industries, headquartered in the United States. Their innovative approach bridges the gap between digital pathology, spatial biology, and molecular testing, promising to convert every biopsy into a rich source of insight.
With their flagship product, QCPRECISE, QuantumCyte, Inc. facilitates enhanced decision-making in research, diagnostics, and therapeutic development by converting image-based annotations into molecular clarity. This approach empowers stakeholders at every level to make faster and more confident decisions, addressing one of modern medicine's crucial needs.
The firm recently secured a $1.05M Early VC investment in August 2023. Their team's combined expertise in genomics, diagnostics, software engineering, and product development makes them a formidable player in advancing health technologies.